Last updated: June 3, 2026
Executive summary
Allergan, Inc. v. Sandoz, Inc. | 2:12-cv-00207 is a US patent litigation matter involving Sandoz’s effort to market a generic version of an Allergan drug under Hatch-Waxman. The case’s litigation record is not provided here (claims, asserted patents, Orange Book listing, settlement terms, or court orders), so no accurate, case-specific infringement/validity/indefiniteness findings, damages posture, or exclusivity-override analysis can be produced.
What patents were asserted in Allergan v. Sandoz (2:12-cv-00207) and what did the claims cover?
No patent numbers, asserted claims, or claim charts are provided for Allergan, Inc. v. Sandoz, Inc. | 2:12-cv-00207. Without that information, the patent estate cannot be mapped to infringement theories (composition, formulation, method-of-use, or process) or to likely design-around pathways.
Which Allergan patents were at issue?
None listed.
Which Sandoz product and filing triggered the dispute?
None identified.
Were the theories infringement-by-inclusion, infringement-by-use, or method claims at issue?
None identified.
What did the court decide on infringement, validity, and enforceability?
No docket outcomes, claim construction decisions, summary judgment rulings, injunction rulings, or final judgment text is provided. Without court orders, the analysis cannot be tied to:
- anticipation/obviousness outcomes (35 USC 102/103),
- written description/enablement (35 USC 112),
- indefiniteness (35 USC 112(b)),
- inequitable conduct or prosecution-history estoppel (where raised),
- or noninfringement/invalidity bases.
Did the court construe key claim terms?
No claim construction details provided.
Was there a trial and what were the findings?
No trial or verdict details provided.
What was the disposition and timeline?
No docket timeline provided.
How does the Allergan v. Sandoz litigation fit into the Hatch-Waxman Paragraph IV framework?
A Paragraph IV litigation implies an Orange Book-listed reference drug with an NDC filing and a generic ANDA (or related pathway) that states noninfringement and/or invalidity. The case-specific framework depends on which listed patents were challenged and what the court held.
No Orange Book listing, patent expiry schedule, or FDA approval dates are provided here, so the Paragraph IV posture cannot be linked to:
- trigger dates for 30-month stays,
- whether the court entered an “infringement” decision before the statutory stay expired,
- any final injunction scope,
- or whether a settlement drove an agreed launch date.
When did the exclusivity clock run out, and did the case affect generic market entry?
No exclusivity basis is provided (market exclusivity, orphan exclusivity, pediatric exclusivity, or patent-based exclusivity). Case-specific effects require:
- date of the ANDA submission,
- date of Paragraph IV notice,
- date of court decision or entry of judgment,
- any settlement that waived/limited launch.
No dates or agreements are provided.
Was there a settlement agreement, and what launch terms did it impose?
No settlement terms, consent judgment language, covenant-not-to-sue scope, or stipulated dismissal terms are provided. Without settlement documentation, the litigation-to-commercial translation cannot be stated (launch-at-risk vs. delayed launch; “carve-outs” to certain dosages; authorization for specific labeling).
What is the Orange Book status of the reference-listed patents implicated by this case?
No Orange Book listings (patent numbers, expiration dates, or listed NDCs) are provided. A correct Orange Book status analysis requires:
- the specific reference product,
- the list of Orange Book patents tied to the NDA,
- whether the patents were “drug substance,” “drug product,” or “method of use,”
- and the status as of the docket-critical period.
Which companies are challenging Allergan’s patents and what does the competitive landscape look like?
No other litigants, multiple ANDA filers, or co-defendants are identified for this docket in the provided prompt. The competitive landscape cannot be mapped without the docket’s parties, related cases, and ANDA filers.
How strong was the Allergan patent estate in this case?
Strength analysis requires record-level inputs:
- which patents were asserted,
- claim scope breadth,
- prosecution history,
- cited prior art,
- and judicial credibility signals (claim construction, summary judgment reasoning).
None of that is present.
Did the case impact FDA regulatory milestones for the Sandoz product?
A litigation disposition can affect FDA timing through statutory stays, settlement-driven launch permissions, or blocking injunctions. This requires a mapping between:
- ANDA acceptance/approval timeline,
- labeling negotiations,
- patent dispute resolution timeline.
None of that information is provided.
What generic entry risks existed for Sandoz after 2:12-cv-00207?
At-risk entry risk depends on:
- whether Allergan obtained an infringement judgment for key claims,
- whether the patents were invalidated,
- whether a consent judgment permitted a carve-out,
- and whether any remaining unlitigated patents still blocked approval.
None of those facts are provided.
Key Takeaways
- Allergan, Inc. v. Sandoz, Inc. | 2:12-cv-00207 cannot be analyzed for asserted patents, court decisions, Paragraph IV consequences, exclusivity impacts, settlement terms, or FDA milestone effects because the underlying docket content is not included in the request.
- No case-specific patent-expiration, Orange Book, injunction, or launch-date analysis can be produced without patent numbers and outcome documents.
FAQs
- What does a 2:12-cv-00207 Hatch-Waxman filing typically signal for generic entry timing?
- How do Paragraph IV outcomes usually translate into FDA approval or launch at risk?
- What factors most often determine claim construction in ANDA patent cases like Allergan v. Sandoz?
- When do settlement agreements in generic patent cases restrict labeling or dosage-form launch?
- How do remaining unchallenged Orange Book patents block generic approval even after a favorable decision?
References
- (No cited sources provided in the prompt.)
